Localized paclitaxel delivery

International Journal of Pharmaceutics

Volumn 183, Issue 2, 1999, Pages 85-100

  Dhanikula, Anand Babu ^a   Panchagnula, Ramesh ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Angiogenesis; Drug delivery system; Localized delivery; Paclitaxel

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ADRENALIN; ANGIOGENESIS INHIBITOR; CARMUSTINE; CHLORPHENIRAMINE; COPOLYMER; CORTICOSTEROID; CREMOPHOR; DEXAMETHASONE; DIPHENHYDRAMINE; GLYCOLIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; MICROSPHERE; MYRISTIC ACID ISOPROPYL ESTER; PACLITAXEL; POLY(ORTHO ESTER); POLYANHYDRIDE; POLYCAPROLACTONE; POLYMER; POLYPROPYLENE; RANITIDINE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG TARGETING; HUMAN; IMPLANT; METASTASIS; MOUSE; NONHUMAN; PASTE; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE; DRUG DELIVERY SYSTEMS; FORECASTING; HUMANS; NEOPLASMS; PACLITAXEL; REGIONAL BLOOD FLOW;

EID: 0033036557     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00087-3     Document Type: Review

References (80)

1. Allwood M., Martin H. The extraction of diethylhexylphthalate (DEHP) from polyvinyl chloride components of intravenous infusion containers and administration sets by paclitaxel injection. Int. J. Pharm. 127:1996;65-71.
2. Augustin H.G. Antiangiogenic tumor therapy: will it work? Trends Pharmacol. Sci. 19:1998;216-228.
3. Ausprunk P.H., Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during angiogenesis. Microvasc. Res. 14:1977;53-65.
4. Axel D.I., Kumert W., Goggelmann C., Oberhoff M., Herdeg C., Kuther A., Wild D.H., Brehm B.-R., Riessen R., Koveker G., Karsch K.R. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 96:1997;636-645.
5. Bouvet M., Ellis L.M., Nishizaki M., Fujiwara T., Liu W.B., Bucana C.D., Fang B.L., Lee J.J., Roth J.A. Adenovirus-mediated wild type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. 58:1998;2288-2292.
6. Boye D.B., Kolonias D., Lampidis T.J. Antiproliferative activity of taxol on human tumor and normal breast cells vs effects on cardiac cells. Int. J. Cancer. 60:1995;571-575.
7. 3 for angiogenesis. Science. 264:1994;569-571.
8. Brown P.D., Levy A.T., Margulies I., Liotta L., Stetler Stovenson W.G. Independent expression and cellular processing of the 72 kDa type IV collagenase and interstitial collagenase in human tumerogenic cell lines. Cancer Res. 50:1990;6184-6191.
9. Burt H.M., Jackson J.K., Bains S.K., Liggins R.T., Oktaba A.M.C., Arsenault A.L., Hunter W.L. Controlled delivery of taxol microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid). Cancer Lett. 88:1995;73-79.
10. Dabur, 1994. Intaxel, Administration guide. Dabur Pharmaceuticals, New Delhi, India.
11. Dedrick R.L. Arterial drug infusion: pharmacokinetic problems and pitfalls. J. Natl. Cancer Inst. 80:1988;84-89.
12. cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ. 5:1994;1041-1050.
13. Dordunoo S.K., Jackson J.K., Arsenault L.A., Oktaba A.M.C., Hunter W.L., Burt H.M. Taxol encapsulation in poly (ε-caprolactone) microspheres. Cancer Chemother. Paharmacol. 36:1995;279-282.
14. Dordunoo S.K., Oktaban A.M.C., Hunter W., Min W., Cruz T., Burt H.M. Release of taxol from poly(ε-caprolactone) pastes: effect of water soluble additives. J. Control. Rel. 44:1997;87-94.
15. Eckman W.W., Patlak C.S., Fenstermacher J.D. A critical evaluation of the principles governing the advantages of intra-arterial infusions. J. Pharm. Biopharm. 2(3):1974;257-285.
16. Ezekowitz R.A., Mullikan J.B., Folkman J. Interferon alfa-2a therapy for 'life-threatening' hemangiomas of infancy. N. Engl. J. Med. 326:1992;1456-1463.
17. Fidler I.J., Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 79:1994;185-188.
18. Folkman J., Watson K., Ingber D., Hanaban D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339:1989;58-61.
19. Folkman J., Cole P., Zimmerman S. Tumor behavior in isolated perfused organs: in vitro growth and metastasis of biopsy material in rabbit thyroid and canine intestinal segment. Ann. Surg. 164:1996;491-502.
20. Fujimoto S., Miyajaki M., Endoh F., Takahashi O., Okui K., Morimoto Y. Biodegradable mitomycin C microspheres given intra-arterially for inoperable hepatic cancer. Cancer. 56:1985;2404-2410.
21. Fung L.K., Ewend M.G., Sills A., Sipos E.P., Thompson R., Watts M., Colvin O.M., Brem H., Saltzman W.M. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroxy-cyclophosphamide and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res. 58:1998;672-684.
22. Gasparini G., Harris A.L. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J. Clin. Oncol. 13:1995;765-782.
23. Gianni L., Kearns C.M., Giani A., Capri G., Vigano L., Locatelli A., Bonadonna G., Egorin M.J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 13:1995;180-190.
24. Gottesman M. The role of proteases in cancer. Semin. Cancer Biol. 1:1990;97-160.
25. Gregory R., DeLisa A.F. Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Clin. Pharm. 12:1993;401-415.
26. Gyves J.W., Ensminger W.D., VanHarken D., Nienderhuber J., Stetson P., Walker S. Improved regional selectivity of hepatic arterial mitomycin by starch microspheres. Clin. Pharmacol. Ther. 34:1983;259-265.
27. Heimans J.J., Vermorken J.B., Wolbers G.J., Eeltink C.M., Meijer W.M., Taphoorn M.J.B., Beijnen J.H. Paclitaxel concentrations in brain tumor tissue. Ann. Oncol. 5:1994;951-953.
28. Hori A., Sasada R., Matsutami E., Naito K., Sakura Y., Fujita T., Kozai Y. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. 51:1991;6180-6184.
29. Ichihara T., Sakamoto K., Mori K., Akagi M. Transcatheter arterial chemoembolization therapy for hepatocellular carcinoma using polylactic acid microspheres containing aclarubicin hydrochloride. Cancer Res. 49:1989;4357-4362.
30. Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H., Folkman J. Synthetic analogues of fumagallin which inhibit angiogenesis and suppress tumor growth. Nature. 348:1990;555-557.
31. Jampel H.D., Leong K., Koya P., Quigley H.A. In vitro release of hydrophobic drugs from polyanhydride disks. Ophthal. Surg. 22:1991;676-680.
32. Kalebic T., Garbisa S., Glaser B., Liotta L.D. Basement membrane collagen: degradation by migrating endothelial cells. Science. 221:1983;281-283.
33. Kamei, S., Okada, H., Inoue, Y., Yoshioka, T., Ogawa, Y., Toguchi, H., 1993. Antitumor effects of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. J. Pharmacol. Exp. Ther. 264, 469-473.
34. Kato T., Nemoto R., Mori H., Kumagai I. Sustained properties of microencapsulated mitomycin C with ethylcellulose infused into renal artery of dog. Cancer. 46:1980;14-21.
35. Kim K.J., Li B., Winer J., Armanini M., Gillet N., Phillip H.S., Ferrara N. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumor growth in vivo. Nature. 362:1993;841-844.
36. Klauber N., Paranji S., Flynn E., Hamel E., D'Amato R.J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57(1):1997;81-86.
37. Knighton D., Ausprunk D., Tapper D., Folkman J. Avascular and vascular phases of tumor growth in the chick embryo. Br. J. Cancer. 35:1977;347-356.
38. Kohler D., Goldspiel B.R. Paclitaxel (Taxol). Pharmacotherapy. 14:1994;3-34.
39. Kramer I., Heuser A. Paclitaxel pharmaceutical and pharmacological issues. Eur. Hosp. Pharm. 1:1995;37-41.
40. Kuhn J. Pharmacology and pharmacokinetics of paclitaxel. Ann. Pharmacother. 28:1994;s15-17.
41. Kwan J.W. High technology i.v. infusion devices. Am. J. Hosp. Pharm. 48:1991;S36-51.
42. Levin V.A. Relationships of octanol/water partition coefficients and molecular weight to rat brain capillary permeability. J. Med. Chem. 23:1980;682-684.
43. Lien W., Ackerman N. The blood supply of experimental liver metastasis: II. A microcirculatory study of tumor and normal vessels of the liver with the use of perfused silicone rubber. Surgery. 68:1970;334-340.
44. Liotta L.A., Tryggvason K., Garbisa S., Hart I., Fottz C.M., Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 284:1980;67-68.
45. Liotta L., Kleinerman J., Saldel G. Quantitative relationship of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. 34:1974;997-1004.
46. Lopes N.M., Adams E.G., Pitts T.W., Bhuyan B.K. Cell kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol. 32:1993;235-242.
47. Markman M., Rowinsky E., Hakes T., Reichman B., Jones W., Lewis J.L., Rubin S., Curtin J., Barakat R., Phillips M. Phase I trial of intraperitoneal taxol: a gynecologic oncology group study. J. Clin. Oncol. 10(9):1992;1485-1491.
48. Markman M., Francis P., Rowinsky E., Hoskins W. Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer? Semin. Oncol. 22(3 Suppl. 6):1995;84-87.
49. Mead Johnson Oncology Products, 1997. Taxol (paclitaxel) for Injection Concentrate Prescribing Information. Bristol Myers Squibb, Princeton, NJ.
50. Merkli A., Heller J., Tabalabay C., Gurny R. The use of acidic and basic excipients in the release of 5-flurouracil and mitomycin C from semisolid bioerodible polyorthesters. J. Control. Rel. 33:1995;415-421.
51. Mignatti P., Tsuloi R., Robbins E., Rifkin D.B. In vitro angiogenesis on human amniotic membrane: requirement for basic fibroblast growth factor induced proteinases. Cell Biol. 108:1989;671-682.
52. Mysliwski A., Szmit E., Szatkowski D., Sosnowska D. Suppression of growth of Bomirski Ab melanoma and its metastasis in hamsters by angiogenesis inhibitor TNP-470. Jpn. J. Cancer. 18:1998;441-444.
53. Nakajima M., Lotan D., Baig M.M., Carralero R.M., Wood W.R., Hendrix H.S.C., Loton R. Inhibition of retinoic acid of type IV collagenolysis and invasion through reconstituted basement membrane by metastatic rat mammary adenocarcinoma cells. Cancer Res. 49:1989;1698-1706.
54. Nightingale S. Treatment IND/group C distribution for advanced metastatic ovarian cancer. J. Am. Med. Assoc. 268:1992;1390-1393.
55. Ohkouchi, K., Imoto, H., Takakura, Y., Hashida, M., Sezaki, H., 1990. Disposition of anticancer drugs after bolus arterial administration in a tissue isolated tumor perfusion system. Cancer Res. 50, 1640-1644.
56. Panchagnula R. Pharmaceutical aspects of paclitaxel. Int. J. Pharm. 172:1998;1-15.
57. Park E.-S., Maniar M., Shah J.C. Biodegradable polyanhydride devices of cefazolin sodium, bupivacaine, and taxol for local drug delivery: preparation and kinetics and mechanism of in vitro release. J. Control. Rel. 52:1998;179-189.
58. Perez E.A. Paclitaxel and cardiotoxicity. J. Clin. Oncol. 16(11):1998;3481-3482.
59. Pinholt E.M., Solheim E., Sudmann E. Bone induction by composite of bioerodible polyorthoesters and demineralized bone matrix in rats. Acta. Orthop. Scand. 62:1991;466-480.
60. Reich R., Thompson E., Iwamoto Y., Martin G.R., Deason J.R., Fuller G.C., Miskin R. Effects of inhibitors of plasminogen activator, serine proteinases and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res. 48:1988;3307-3312.
61. Rowinsky E.K., Cazenave L.A., Donehower R.C. Taxol: a novel investigational antimicrotubular agent. J. Natl. Cancer Inst. 82(15):1990;1247-1259.
62. Rowinsky E., Donehower RC. Paclitaxel (Taxol). N. Eng. J. Med. 332:1995;1004-1014.
63. Schiff P., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature. 277:1979;665-667.
64. Song D., Hsu Li.F., Au L.-S. Binding of taxol to plastic and glass containers and protein in vitro conditions. J. Pharm. Sci. 85:1996;29-31.
65. Song D., Wientjes M.G., Au J.L. Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother. Pharmacol. 40(4):1997;285-292.
66. Sonnichsen D.S., Relling M.V. Clinical pharmacokinetics of paclitaxel. Clin. Pharmacokinet. 27(4):1994;256-269.
67. Spencer C.M., Faulds D. Paclitaxel: a review of its pharmacodynamic and pharmaco-kinetic properties and therapeutic potential in the treatment of cancer. Drugs. 48(5):1994;794-847.
68. Stearns M.E., Wang M. Taxol blocks processes essential for prostate tumor cell (PC-3ML) invasion and metastases. Cancer Res. 52:1992;3776-3781.
69. Tai-Ping D., Jagger R., Bicknell R. Controlling the vasculature: angiogenesis, antiangiogenesis and vascular targeting of gene therapy. Trends Pharmacol. Sci. 16:1995;57-66.
70. Teicher B.A., Sotomayer E.L., Huang Z.D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 52:1992;6702-6704.
71. Walker T.L., DeCruz E.E., Dass C.R., Burton M.A. A method for intratumoral continuous infusion of antisense oligodeoxynucleotides. J. Pharm. Sci. 87:1998;387-389.
72. Walter K.A., Cahan M.A., Gur A., Tyler B., Hilton J., Colvin O.M., Burger P.C., Domb A., Brem H. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res. 54:1994;2207-2212.
73. Wang M., Stearns M.E. Blocking of collagenase secretion by estamustine during in vitro tumor cell invasion. Cancer Res. 48:1988;6262-6271.
74. Wang Y.M., Sato H., Adachi I., Horikoshi I. Preparation and characterization of poly (lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, taxol. Chem. Pharm. Bull. (Tokyo). 44(10):1996;1935-1940.
75. Wang Y.M., Sato H., Horikoshi I. In vitro and in vivo evaluation of taxol release from poly (lactic-co-glycolic acid) microspheres containing isopropyl myristate and degradation of the microspheres. J. Control. Rel. 49:1997;157-166.
76. Weidner N., Semple S.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N. Engl. J. Med. 324:1991;1-8.
77. Winternitz C.I., Jackson J.K., Okataba A.M.C., Burt H.M. Development of a polymeric surgical paste formulation for taxol. Pharm. Res. 13(3):1996;368-375.
78. Yanai S., Okada H., Saito K., Kuge Y., Misaki M., Ogawa Y., Toguchi H. Antitumor effect of arterial administration of a medium chain triglyceride solution of an angiogenesis inhibitor, TNP-470 in rabbits bearing VX-2 carcinoma. Pharm. Res. 12(5):1995;653-657.
79. Yen W-C., Wientjes M.G., Au J.L-S. Differential effect of taxol in rat primary and metastatic prostrate tumors: site dependent pharmacodynamics. Pharm. Res. 13(9):1996;1305-1312.
80. Zhang X., Jackson J.K., Wong W., Min W., Cruz T., Hunter W.L., Burt H.M. Development of biodegradable polymeric paste formulations for taxol: an in vitro and in vivo study. Int. J. Pharm. 137:1996;199-208.